Chronic Obstructive Pulmonary Disease (COPD) Market Research Report - Forecast till 2027

Chronic Obstructive Pulmonary Disease (COPD) Market Research Report: Information by COPD Type (Emphysema and Chronic Bronchitis), Treatment Type (Drugs, Surgery and Oxygen Therapy), End User (Hospitals & Clinics, Home Care Settings and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1081-HCR | February 2021 | Region: Global | 90 pages

Chronic Obstructive Pulmonary Disease (COPD) Market Overview

Chronic obstructive pulmonary disease is a chronic disorder of the lungs that inhibits the airflow to the lungs. Globally it has been noticed that the factor lying behind this disorder is the rise in the number of cases within the public. Revolution in the lifestyle of the people like to enhance in their habits of smoking and drinking and besides it, many other genetic diseases have increased the chronic obstructive pulmonary disease cases. Spending money on healthcare is enhancing the facilities in developing countries for COPD. Arranging rallies for making them aware of chronic pulmonary disease across developed and underdeveloped countries have increased the growth of the chronic obstructive pulmonary disease market. Research has been still carried out to solve the complexity of the market situations faced in this sector. The key players so present follows the chronic obstructive pulmonary disease market trend giving the right solutions to the client’s problems by using the right methods of their research. 


Chronic Obstructive Pulmonary Disease (COPD) Market is expected to register a CAGR of 4.5% to touch USD 25.7 Billion from 2020 TO 2027.


COVID 19 ANALYSIS 


The breakdown of COVID has become a risk factor for chronic obstructive pulmonary disease. Initially, it was in less count and gradually it increased. Due to this situation, the supply of respiratory ailment devices to the hospitals was hindered in most of the places. Patients suffering from both COVID and COPD were undergoing with worst ailment conditions. COVID situation brought no significant difference in the condition of the chronic obstructive pulmonary disease patients. The public during this situation was advised to stay indoors and will only move out if they had to concern a doctor. They were advised to move with proper precautions liking wearing masks, gloves and hair caps, etc.


It has affected the COPD market and its prolonged effect will have a bad impact on the market during the chronic obstructive pulmonary disease forecast period. From chronic obstructive pulmonary disease market analysis, you can notice the change in consumer behavior and their demand thus affected the supply chain. Some of the policies and certain regulations regarding the COVID are put forward by the government. The government has imposed strict rules and regulations against COVID.



Regional Market Summary


Global Chronic Obstructive Pulmonary Disease (COPD) Market Share (%), by Region, 2018


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


MARKET DYNAMICS



  • Drivers- donating of larger funds from government and pharmaceutical companies for manufacture and launching of new drugs and R and D drives up the chronic obstructive pulmonary disease market value. The rise in incidence and the prevailing condition of asthma and COPD and the rise in the geriatric population are the major driving factors of the COPD market.

  • Opportunities- government making allowance for the drugs and biosimilars provides great opportunities for the chronic obstructive pulmonary disease global market value. Advancement of the hospital infrastructure, lifestyle changes, and disposable income are the factors that make the CPOD market to be at the top.

  • Challenges- launching a new product is the major challenge for the market. Depending on its advantage and disadvantage the positive and its negative effects poses severe challenges on the chronic obstructive pulmonary disease global market. Demand for homecare therapeutic instruments and devices becomes a challenging factor for the CPOD market.

  • Cumulative growth - Chronic obstructive disease has been prevailing in the world for since long. Development of new products and launching them as per new technology is steering up the chronic obstructive pulmonary disease market growth. The increase in demand for the drugs for the suffering persons targetting their treatment boosts the growth. Researchers are still now carrying research for evaluation of their efficacy which will be safer for the patients.

  • Restraints- spending a large amount on COPD treatment and having fewer ideas and knowledge about the disease are the major restraints affecting the chronic obstructive pulmonary disease global market growth Patent expiry is the anothe4r factor affecting the growth and chronic obstructive pulmonary disease industry value. Patients responding negatively to combination therapy act as a restraint to chronic obstructive pulmonary disease industry growth. The demand for generic drugs has affected the growth and manufacture of drugs. Strict government regulations for the manufacture and launching of new products act as major restraints for the market. 


VALUE CHAIN ANALYSIS 


The value chain analysis offers the idea of revenue generation into the overall market space. It provides insights about how vendors are practicing and carrying out in terms of revenue generation and customer base case. Having ideas about the market share and the competitiveness and the chronic obstructive pulmonary disease market size. The COPD market also gives information about the characteristics of the chronic obstructive pulmonary market value.


SEGMENT OVERVIEW



  • By type- as per the type, the chronic obstructive pulmonary disease is bifurcated into chronic bronchitis and emphysema. Emphysema leads to the wear and tear of the fragile elastic walls and fibers of alveoli. During exhalation, the airways collapse impairing the airflow while in the former case causing inflammation of bronchial tubes leading to the production of more mucus. The chronicle market is divided into hospitals, clinics, home care settings, and many others. Hospitals and clinics are dominant and cover a large part of the chronic obstructive pulmonary disease market share.

  • By technology- the advancement of technology increases the opportunities for advanced treatment of COPD. Advanced technology encourages the development of drugs, thus increasing the chronic obstructive pulmonary diseases market size. Technology has been applied in every field like in the medical sector which has improved the mapping of COPD epidemiology. It has cleared our understanding of the disease and has imposed the development of therapies in the COPD market. The drugs and the diagnosis so carried out show promising consequences that are efficient enough. Technology has provided end-to-end solutions for every disease. 


REGIONAL ANALYSIS


North America is expected to be the first dominant region covering a large area of market share. The Asia Pacific is marked to be the next dominant market covering the largest portion due to its large population ratio. Asia Pacific region includes the regions of Indonesia, Philippines, China, some portions of Thailand, and India. Developed by revenue COPD in North America covers a chronic obstructive pulmonary disease market share followed by Europe. All the above regions form a constant array of chains carrying out new methods and formulas for the discovery of the drug. The prevalence of the drug market in Japan has helped the region to flourish in a better way. These regions have strengthened their positions in the chronic obstructive pulmonary disease industry.


COMPETITIVE LANDSCAPE 


Some competitors of the COPD in the chronic obstructive pulmonary disease market include Abbott Laboratories in the US, Circassia Pharmaceuticals in the UK, Almirall in Spain, Japan’s Astellas Pharma, AstraZeneca of United Kingdom, United Kingdom’s GlaxoSmithKline, Novartis of Switzerland, Pfizer, Teva Pharmaceutical Industries Ltd, Boeringhar Ingelheim of Germany, etc. these competitors involve in merging and making partnership with other countries. They carry out various expansion strategies and adopting the new chronic obstructive pulmonary disease market outlook for various marketing penetration. By following the chronic obstructive pulmonary disease industry outlook they are launching new products and are carrying out acquisitions which helps in substantial chronic obstructive pulmonary disease industry growth. Before collaborating they take license for consolidation of their product portfolio. 


REPORT OVERVIEW 


Globally the chronic obstructive pulmonary disease market is providing a good evaluation about the chronic obstructive pulmonary disease market outlook. It also provides a good analysis of the drivers, its segment overview, restraints, and the challenges that are being prolonged in the chronic marketing sector. This market analysis gives a holistic insight into the market globally. It also entitles the financial statement of the competitors with product benchmarking and SWOT analysis. It emphasizes the developmental strategies put forward by the key players and their rank order in the market. The segmentation so done in the marketing sector shows the expansion of chronic obstructive pulmonary disease market size and chronic obstructive disease market outlook. It also assesses and gives a clear picture of the qualitative and quantitative techniques which assists the clients which increases their skills to make the proper decision regarding the business.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: 25.7 Billion
  CAGR   4.7% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   COPD Type, Treatment Type and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)
  Key Market Opportunities   People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions
  Key Market Drivers

  • high prevalence of chronic respiratory diseases
  • increasing demand for home care therapeutic devices


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The valuation of the global chronic obstructive pulmonary disease (COPD) market had reached USD 25.7 Billion By 2027

    The main types of chronic obstructive pulmonary disease (COPD) are emphysema and chronic bronchitis.

    The treatments included in the Chronic Obstructive Pulmonary Disease Treatment (COPD) Market are Drugs, Surgery and Oxygen Therapy.

    Technological advancements and new product launches and increasing demand for home care therapeutic devices are the major tailwinds pushing the growth of the global chronic obstructive pulmonary disease (COPD) market.

    North America holds the largest share in the chronic obstructive pulmonary disease (COPD) market, followed by Europe and the Asia Pacific, respectively.

    AstraZeneca (UK), Abbott (USA), Dr. Reddy’s Laboratories Ltd (India), GSK (UK), F. Hoffmann-La Roche Ltd (Switzerland), Merck (USA), Pfizer Inc. (USA), and Novartis AG (Switzerland), are some of the major players operating in the chronic obstructive pulmonary disease (COPD) market.

    The chronic obstructive pulmonary disease (COPD) market is projected to grow at approximately 4.7% CAGR during the assessment period (2020-2027)

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis


    6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE

    6.1. Overview

    6.2. Emphysema

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Chronic Bronchitis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE

    7.1. Overview

    7.2. Drugs

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.1. Bronchodilator Monotherapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.1.1. Short-Acting Beta2-Agonists (SABAs)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.1.2. Long-Acting Beta2-Agonists (LABAs)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.1.3. Anti-Cholinergic Agent

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.2. Anti-Inflammatory Drugs

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.2.1. Oral and Inhaled Corticosteroids

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.2.2.2. Anti-Leukotrienes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Surgery

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3.1. Lung Volume Reduction Surgery (LVRS)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3.2. Lung Transplant

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3.3. Bullectomy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Oxygen Therapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER

    8.1. Overview

    8.2. Hospitals and Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Homecare Settings

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa

    10. COMPANY LANDSCAPE

    10.1. Overview

    10.2. Competitive Analysis

    10.3. Market Share Analysis

    10.4. Major Growth Strategy in the Global Chronic Obstructive Pulmonary Disease (COPD) Market

    10.5. Competitive Benchmarking

    10.6. Leading Players in Terms of the Number of Developments in the Global Chronic Obstructive Pulmonary Disease (COPD) Market

    10.7. Key Developments and Growth Strategies

    10.7.1. Product Launch/Service Deployment

    10.7.2. Mergers and Acquisitions

    10.7.3. Joint Ventures

    10.8. Major Players Financial Matrix & Market Ratio

    10.8.1. Sales & Operating Income 2020

    10.8.2. Major Players R&D Expenditure 2020

    10.9. Major Players Capital Market Ratio

    11. COMPANY PROFILES

    11.1. Abbott Laboratories

    11.1.1. Company Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Almirall

    11.2.1. Company Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. Astellas Pharma

    11.3.1. Company Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. AstraZeneca

    11.4.1. Company Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. Boehringer Ingelheim

    11.5.1. Company Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Circassia Pharmaceuticals

    11.6.1. Company Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. GlaxoSmithKline plc

    11.7.1. Company Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Novartis AG

    11.8.1. Company Overview

    11.8.2. Product Overview

    11.8.3. Financial Overview

    11.8.4. Key Developments

    11.8.5. SWOT Analysis

    11.8.6. Key Strategies

    11.9. Pfizer, Inc.

    11.9.1. Company Overview

    11.9.2. Product Overview

    11.9.3. Financial Overview

    11.9.4. Key Developments

    11.9.5. SWOT Analysis

    11.9.6. Key Strategies

    11.10. Teva Pharmaceutical Industries Ltd

    11.10.1. Company Overview

    11.10.2. Product Overview

    11.10.3. Financial Overview

    11.10.4. Key Developments

    11.10.5. SWOT Analysis

    11.10.6. Key Strategies

    11.11. Others

    12. APPENDIX

    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 10 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 11 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 12 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 13 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 14 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 15 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 19 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 20 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 21 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET

    FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET

    FIGURE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COPD TYPE, 2020 (%)

    FIGURE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

    FIGURE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 7 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 7 AMERICAS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE BY REGION, 2020 (%)

    FIGURE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 9 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS

    FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

    FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

    FIGURE 17 ALMIRALL: KEY FINANCIALS

    FIGURE 18 ALMIRALL: SEGMENTAL REVENUE

    FIGURE 19 ALMIRALL: REGIONAL REVENUE

    FIGURE 20 ASTELLAS PHARMA: KEY FINANCIALS

    FIGURE 21 ASTELLAS PHARMA: SEGMENTAL REVENUE

    FIGURE 22 ASTELLAS PHARMA: REGIONAL REVENUE

    FIGURE 23 ASTRAZENECA: KEY FINANCIALS

    FIGURE 24 ASTRAZENECA: SEGMENTAL REVENUE

    FIGURE 25 ASTRAZENECA: REGIONAL REVENUE

    FIGURE 26 BOEHRINGER INGELHEIM: KEY FINANCIALS

    FIGURE 27 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE

    FIGURE 28 BOEHRINGER INGELHEIM: REGIONAL REVENUE

    FIGURE 29 CIRCASSIA PHARMACEUTICALS: KEY FINANCIALS

    FIGURE 30 CIRCASSIA PHARMACEUTICALS: SEGMENTAL REVENUE

    FIGURE 31 CIRCASSIA PHARMACEUTICALS: REGIONAL REVENUE

    FIGURE 32 GLAXOSMITHKLINE PLC: KEY FINANCIALS

    FIGURE 33 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

    FIGURE 34 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

    FIGURE 35 NOVARTIS AG: KEY FINANCIALS

    FIGURE 36 NOVARTIS AG: SEGMENTAL REVENUE

    FIGURE 37 NOVARTIS AG: REGIONAL REVENUE

    FIGURE 38 PFIZER, INC.: KEY FINANCIALS

    FIGURE 39 PFIZER, INC.: SEGMENTAL REVENUE

    FIGURE 40 PFIZER, INC.: REGIONAL REVENUE

    FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

    FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

    FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE